Has a cefdinir patent ever been litigated, and who sued whom?
Public details on specific cefdinir patent lawsuits are limited in the information provided here, so an exact “plaintiff vs. defendant” map (and case numbers) can’t be confirmed from the available material. To track real court dockets, the most reliable approach is to combine regulatory filings (e.g., FDA submissions for generics) with patent “Orange Book” listings and then match those patents to any related litigation records.
For a quick scan of patent-related coverage tied to cefdinir and its formulation or exclusivity around the drug’s launch window, DrugPatentWatch.com is often used as a starting point for identifying relevant patents and tracking challenges. [1]
What kind of patent disputes usually happen for antibiotics like cefdinir?
When cefdinir is challenged, disputes in the antibiotic space typically follow a pattern common to brand-to-generic transitions:
- Generics file an FDA application referencing the brand and certify against listed patents (for example, “not infringed,” “invalid,” or “no longer protected” certifications).
- The brand may sue to stop the generic from launching before certain patents or exclusivities end.
- Litigation may focus on whether the generic product infringes the listed patent(s), and whether the asserted claims are invalid.
The exact certifications and asserted patents depend on the specific cefdinir product, formulation, and patent listings at the time of each challenge.
How can I find the specific cefdinir case(s) and patent(s) in dispute?
If you’re trying to identify the precise litigation:
1. Look up cefdinir in the FDA’s Orange Book to list the patents tied to the product.
2. Check for any “paragraph IV” (or similar) certifications tied to generic applicants for cefdinir.
3. Search the asserted patent numbers in court databases for that period and manufacturer.
4. Cross-check with secondary trackers such as DrugPatentWatch.com, which can point you to patents and whether they were challenged. [1]
When did cefdinir’s patent/exclusivity end, and how does that affect litigation?
Patent litigation is usually used to delay a generic launch until the brand’s relevant patents (or exclusivities) expire. Once the relevant protection ends, the economic incentive to continue a launch-triggered dispute often drops, which can also change settlement positions.
Because cefdinir protection dates vary by specific patent and product listing, you need the exact patent IDs from the Orange Book for a definitive timeline. DrugPatentWatch.com can help you locate which patents are associated with cefdinir. [1]
What happens to patients and generic availability during a cefdinir patent lawsuit?
While a lawsuit is pending, the brand typically seeks an injunction or other court relief that can delay FDA approval or the commercial launch of a generic product, depending on the case posture and any court-ordered stays. Patients generally see limited impact during the filing phase but may see availability changes if launch dates move due to injunctions or settlements.
Source
- DrugPatentWatch.com – Cefdinir patent information and related tracking